Bellicum Pharmaceuticals, Inc. (BLCM) Trading Up 0% After Strong Earnings

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) shares were up 0% during mid-day trading on Wednesday following a better than expected earnings announcement. The stock traded as high as $10.66 and last traded at $10.39. Approximately 647,473 shares changed hands during trading, an increase of 84% from the average daily volume of 352,444 shares. The stock had previously closed at $10.39.

The biopharmaceutical company reported ($0.71) EPS for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.03. Bellicum Pharmaceuticals had a negative return on equity of 74.34% and a negative net margin of 17,957.31%. The business had revenue of $0.13 million during the quarter, compared to analysts’ expectations of $0.03 million. During the same quarter last year, the company posted ($0.66) earnings per share. Bellicum Pharmaceuticals’s quarterly revenue was up 18.2% on a year-over-year basis.

BLCM has been the subject of a number of research analyst reports. BidaskClub upgraded Bellicum Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, August 25th. Jefferies Group LLC reiterated a “buy” rating and set a $16.00 price target on shares of Bellicum Pharmaceuticals in a report on Thursday, September 14th. Zacks Investment Research upgraded Bellicum Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, October 24th. ValuEngine upgraded Bellicum Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Monday, September 18th. Finally, Raymond James Financial, Inc. set a $18.00 price target on Bellicum Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, August 9th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $26.20.

Several large investors have recently modified their holdings of the company. Principal Financial Group Inc. boosted its holdings in shares of Bellicum Pharmaceuticals by 0.7% during the first quarter. Principal Financial Group Inc. now owns 83,338 shares of the biopharmaceutical company’s stock worth $1,029,000 after acquiring an additional 610 shares during the period. American International Group Inc. boosted its holdings in shares of Bellicum Pharmaceuticals by 7.1% during the first quarter. American International Group Inc. now owns 12,902 shares of the biopharmaceutical company’s stock worth $159,000 after acquiring an additional 852 shares during the period. Bank of New York Mellon Corp boosted its holdings in shares of Bellicum Pharmaceuticals by 1.0% during the first quarter. Bank of New York Mellon Corp now owns 95,934 shares of the biopharmaceutical company’s stock worth $1,184,000 after acquiring an additional 935 shares during the period. ProShare Advisors LLC boosted its holdings in shares of Bellicum Pharmaceuticals by 14.9% during the second quarter. ProShare Advisors LLC now owns 19,393 shares of the biopharmaceutical company’s stock worth $227,000 after acquiring an additional 2,513 shares during the period. Finally, Nationwide Fund Advisors boosted its holdings in shares of Bellicum Pharmaceuticals by 30.4% during the second quarter. Nationwide Fund Advisors now owns 15,530 shares of the biopharmaceutical company’s stock worth $181,000 after acquiring an additional 3,620 shares during the period. Institutional investors own 55.87% of the company’s stock.

The company has a debt-to-equity ratio of 0.22, a quick ratio of 8.34 and a current ratio of 8.34.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this piece of content on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The legal version of this piece of content can be read at https://sportsperspectives.com/2017/11/10/bellicum-pharmaceuticals-inc-blcm-trading-up-0-after-strong-earnings.html.

About Bellicum Pharmaceuticals

Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.

Receive News & Ratings for Bellicum Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply